EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies

Gloria Arena, Roberto Chiarle

Cancers · 28.10.2025 · 17 (21) · 3453

DOI: 10.3390/cancers17213453 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.10.2025. Verfasst von Gloria Arena und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, AIRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment paradigms for B-cell lymphomas have evolved significantly in the last decades. Nevertheless, the widespread clinical use of immunotherapy has demonstrated that it invariably leads to the development of resistance. This review outlines the underlying molecular mechanisms of resistance associated with emerging immunotherapeutic strategies, including Chimeric Antigen Receptor (CAR) T cell therapy and bispecific antibodies (BsAbs). In high-grade B-cell lymphomas, nearly 50% of patients progress following CAR T treatment due to host-related factors affecting CAR T cell proliferation and persistence, as well as tumor-intrinsic factors, such as loss of CD19 epitope expression, trogocytosis, and other genomic alterations (e.g., CD19 mutations, chromothripsis, APOBEC mutational activity, and deletions of RHOA). Additional genomic and epigenetic events, including mutations, alternative splicing of CD19, and aberrant promoter methylation, further contribute to resistance. BsAbs, representing an off-the-shelf T-cell-redirecting strategy, have recently shown promising single-agent efficacy with a manageable toxicity profile, predominantly characterized by T cell overactivation syndromes. Similarly to CAR T cell therapy, BsAb resistance arises through diverse mechanisms, such as antigen loss, T cell dysfunction (exhaustion and regulatory T cell activation), tumor-intrinsic alterations (e.g., TP53 mutations and MYC amplifications), and immunosuppressive influences from the tumor microenvironment. These findings underscore the complexity of immune evasion in B-cell lymphomas and highlight the ongoing need to optimize immunotherapeutic strategies and develop combination approaches to overcome resistance.

Schlagwörter

Stichwörter der Autor:innen

B-cell lymphomasCD19-CAR TChimeric Antigen Receptor T cell therapybispecific antibodiesimmunotherapyresistance

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.
  • Division of Hematopathology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Department of Pathology, Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Förderung

  • Italian Association for Cancer Research
  • AIRC

Zitieren

APA

Arena, G., & Chiarle, R. (2025). Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies. Cancers, 17(21), 3453. https://doi.org/10.3390/cancers17213453

Vancouver

Arena G, Chiarle R. Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies. Cancers. 2025;17(21):3453. doi:10.3390/cancers17213453

BibTeX
@article{Arena2025,
  author = {Arena, Gloria and Chiarle, Roberto},
  title = {Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {21},
  pages = {3453},
  doi = {10.3390/cancers17213453}
}
Kostenlos starten →